|
1186
|
CVD 1208S
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
University of Maryland, Baltimore
|
Clinical - Terminated
|
Oral
|
17938573
|
NCT00866476
|
|
1187
|
Sonnei vaccine 1790GAHB
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Conjugate
|
GlaxoSmithKline
|
Clinical - Phase 1
|
Intramuscular
|
NA
|
NCT03089879
|
|
1188
|
Sf2aWC
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Inactivated
|
PATH
|
Clinical - Withdrawn
|
Oral
|
26865592
|
NCT03038243
|
|
1189
|
SF2a-TT15
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Conjugate
|
University of Maryland, Baltimore
|
Clinical - Suspended
|
Intramuscular
|
33186516
|
NCT04078022
|
|
1190
|
Shigella Conjugate
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Conjugate
|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Clinical - Phase 3
|
NA
|
11179298
|
NCT00368316
|
|
1191
|
Invaplex 50
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Subunit
|
U.S. Army Medical Research and Development Command
|
Clinical - Phase 1, Phase 2
|
Intranasal
|
34258576
|
NCT00485134
|
|
1192
|
O-SPC/rBRU
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Conjugate
|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Clinical - Phase 1
|
Intramuscular
|
NA
|
NCT01369927
|
|
1193
|
Flexyn2a
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Bioconjugate
|
LimmaTech Biologics AG
|
Clinical - Phase 2
|
Intramuscular
|
NA
|
NCT02646371
|
|
1194
|
WRSs2
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
National Institute of Allergy and Infectious Diseases (NIAID)
|
Clinical - Phase 2
|
Oral
|
30037478
|
NCT04242264
|
|
1195
|
WRSs2 and WRSs3
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
National Institute of Allergy and Infectious Diseases (NIAID)
|
Clinical - Phase 1
|
Oral
|
30037478
|
NCT01336699
|
|
1196
|
CVD 1208S-122
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
University of Maryland, Baltimore
|
Clinical - Phase 1
|
Oral
|
32257392
|
NCT04634513
|
|
1197
|
GVXN SD133
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Bioconjugate
|
GlycoVaxyn AG
|
Clinical - Phase 1
|
Intramuscular
|
26162850
|
NCT01069471
|
|
1198
|
SC599
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
Institut Pasteur
|
Clinical - Phase 2
|
Oral
|
19135496
|
NCT00210288
|
|
1199
|
SC602
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
Institut Pasteur
|
Clinical
|
Ingestion
|
10377124
|
NA
|
|
1200
|
CVD1207
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Recombinant
|
NA
|
Clinical - Phase 1
|
Oral
|
10678904
|
NA
|
|
1201
|
Shigella4V
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Bioconjugate
|
LimmaTech Biologics AG
|
Clinical - Phase 1, Phase 2
|
NA
|
NA
|
NCT04056117
|
|
1202
|
WRSS1
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Live attenuated
|
U.S. Army Medical Research and Development Command
|
Clinical - Phase 1, Phase 2
|
Oral
|
30794051
|
NCT01080716
|
|
1203
|
InvaplexAR
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Recombinant
|
U.S. Army Medical Research and Development Command
|
Clinical - Phase 1
|
Intranasal
|
NA
|
NCT02445963
|
|
1204
|
S.Flexneriza-S.Sonnei Bivalent
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Conjugate
|
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
|
Clinical - Phase 2
|
Intramuscular
|
NA
|
NCT04865497
|
|
1205
|
EcSf2a-2
|
Bacillary Dysentery (Shigellosis)
|
Shigella genus
|
Recombinant
|
NA
|
Clinical
|
NA
|
NA
|
NA
|